Minos Stent-Graft in Aneurysm Repair: Real-World Registry Across Europe and Asia
Official title: A Prospective Multi-centre Observational Real-world Post-market European & Asian Registry With Low-profile Minos™ Abdominal Aortic Stent Graft
Run by Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd · NCT07674173 · Data updated 2026-11-12
This study tests how the Minos Abdominal Aortic Stent-Graft performs in everyday clinical use for people with infrarenal abdominal aortic aneurysms.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd Industry-sponsored |
| Locations | 16 sites (Lanzhou, Gansu and 15 other locations) |
| Status | Recruiting |
| Started | March 5, 2023 |
| Main results expected | October 22, 2028 |
| Study ends | January 22, 2033 |
| Registry record updated | June 29, 2026 |
| Trial ID | NCT07674173 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with infrarenal AAA planned for repair using the Minos stent-graft.
✕Probably not a fit
Patients with contraindications to the Minos device or who require alternative aneurysm management may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry collects real-world safety and performance data on the Minos stent-graft and delivery system used to treat infrarenal abdominal aortic aneurysms. It plans to enroll about 200 patients globally, with at least 30 from European hospitals, and follow them for up to five years. Data will come from routine clinical practice at participating centers to understand how the device behaves outside controlled trials. The study focuses on short-, medium-, and long-term outcomes, including device performance, complications, and need for reintervention. No experimental interventions beyond standard implantation are involved.
Why it matters
Potential benefit: If successful, the registry could support safer use of the Minos system and inform clinicians about long-term outcomes in diverse patient populations.
How similar studies have gone: Other post-market registries for endovascular grafts have provided valuable real-world data, supporting broader understanding of device performance.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of infrarenal abdominal aortic aneurysm * Plan to treat with Minos Abdominal Aortic Stent-Graft and Delivery System * Voluntary participation and completion of Informed Consent Form, with willingness to participate in follow-up to 5 years post-procedure Exclusion Criteria: * Subjects in whom use of the Minos™ Abdominal Aortic Stent-Graft and Delivery System is contraindicated, as follows: * Severe stenosis or calcification near the aneurysm, leading to difficulty in achieving apposition of vessel wall and stent graft. * Difficult access due to severe stenosis or tortuosity in the iliac artery or femoral artery. * Subjects with ruptured aneurysm or acute aneurysm. * Subjects with an infectious aneurysm. * Those who are allergic to contrast agents or unable to tolerate contrast agents due to renal insufficiency. * Patients with severe coagulation disorder and/or high risk of postoperative hemorrhage. * Aneurysmal neck angulation greater than 60°. * Patients with blood supply to vital organs originating from the aneurysmal sac. * Patients with other comorbidities and whose life expectancy does not exceed one year. * Subjects with connective tissue diseases, such as Marfan syndrome. * Minors and pregnant women. * Subjects who are allergic to nitinol. * Subjects who are considered not suitable for treatment with stent graft.
Where it's running
-
The Second Hospital of Lanzhou University
Lanzhou, Gansu, China Recruiting -
Meizhou People's Hospital
Meizhou, Guangdong, China Recruiting -
The University of Hong Kong - Shenzhen Hospital
Shenzhen, Guangdong, China Recruiting -
Hunan Provincial People's Hospital
Changsha, Hunan, China Recruiting -
Xiangtan Central Hospital
Xiangtan, Hunan, China Recruiting -
Yueyang Central Hospital
Yueyang, Hunan, China Recruiting
Show 10 more locations
-
Zibo Central Hospital
Zibo, Shandong, China Recruiting -
TEDA International Cardiovascular Hospital
Binhai, Tianjin Municipality, China Recruiting -
Kunming Yan'an Hospital
Kunming, Yunnan, China Recruiting -
Fuwai Hospital
Beijing, China Recruiting -
Klinikverbund Allgäu
Immenstadt im Allgäu, Allgäu, Germany Recruiting -
Universitätsklinikum Münster (UKM)
Münster, Germany Recruiting -
"G. Gennimatas" Thessaloniki General Hospital
Thessaloniki, Greece Recruiting -
Erasmus MC
Rotterdam, Netherlands Recruiting -
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (ASST Spedali Civili di Brescia)
Brescia, Italy Not yet recruiting -
Hospital Universitari de Girona Doctor Josep Trueta
Girona, Catalonia, Spain Not yet recruiting
Study contacts
- Study coordinator: Maggie Shen, MD MSc
- Email: maggie.shen@endovastec-lm.com
- Phone: 00441235750800
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.